A novel drug for against DVT on long-haul flights is being developed by Australian and US scientists
According to The Australian Financial review, researchers from Melbourne's Baker Heart and Diabetes Institute and Harvard Medical School have engineered a novel mechanism that homes in on a clot that has begun to form and blocks its progression.
Deep vein thrombosis, or DVT, is caused by a blood clot, most commonly in the legs.
Sitting in the same position for hours on a plane, together with lower air pressure, less oxygen and less hydration, increases the risk of a DVT developing.
"The drug can do two things," Professor Wang said. "It can prevent a clot from forming and break down one already formed.
"Our hope is that a patient at high risk of DVT, about to take a long-haul flight, can be injected with it. If a clotting process begins, the drug will find its way to the clot, bind to it and prevent it forming."
The same mechanism applies to a heart attack and stroke.
The drug has been proven to work in mice and in human blood.
"From what we have seen so far, there is no reason why it wouldn't work in patients at risk," Professor Wang said.
If you want to read this article in Japanese, please see the following link:
Subscribe to our English Newsletter